Lexaria’s CEO posts end of 2017 summary Multiple transformative developments – IP strengthened, broad patents awarded, finances secured Foundation for the future established &nd… Read More

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development (“R&D”) program; R&D regarding nicotin… Read More

High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018… Read More

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has received a new Notice of Allowance from the United States Patent and Tr… Read More